|Bid||40.25 x 200|
|Ask||40.94 x 2900|
|Day's Range||40.50 - 40.79|
|52 Week Range||37.20 - 45.58|
|PE Ratio (TTM)||45.89|
|Dividend & Yield||1.95 (4.65%)|
|1y Target Est||N/A|
Rating Action: Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings. Global Credit Research- 27 Jul 2017. London, 27 July 2017-- Moody's Investors Service has today changed ...
Both in-house and M&A solutions will be risky and take time to bear fruit.
Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.